MADRID, January 3, 2018 /PRNewswire/ --
PharmaMar (MCE: PHM) has announced the initiation of the re-examination processby the European Medicines Agency (EMA) for AplidinŽ (plitidepsin) for the indication of relapsed and refractory multiple myeloma.
(Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )
PharmaMar believes that this novel
It is worth noting that the re-examination procedure is handled by the EMA´s CHMP and usually lasts around 4 months. It concludes with either the confirmation of the negative opinion or with the issuing of a new positive opinion by the CHMP.
After finalizing this process of re-examination, the European Commission will be in charge of emitting the final verdict on the Marketing Authorization Application (MAA) for AplidinŽ (plitidepsin), which could arrive around June or July, 2018.
Media Relations (+34-6387-96215) and Investor Relations (+34-9144-44500)
Subscribe to our Free Newsletters!
Blood groups are of four important groups determined by the presence or absence of specific ...
Spermatocele is a condition in which there is a blockage in the epididymal duct, resulting in semen ...
Be a blood donor and save lives for your donated blood is separated into blood products or just ...View All